Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Fish and Richardson
Express Scripts
Julphar
Teva
Harvard Business School
Chinese Patent Office
Fuji

Generated: May 21, 2018

DrugPatentWatch Database Preview

REGITINE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Regitine patents expire, and when can generic versions of Regitine launch?

Regitine is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in REGITINE is phentolamine mesylate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
Summary for REGITINE
Drug patent expirations by year for REGITINE
Medical Subject Heading (MeSH) Categories for REGITINE
Synonyms for REGITINE
134P201
2-[N-(m-Hydroxyphenyl)-p-toluidinomethyl]imidazoline Methanesulfonate
2-[N-(m-Hydroxyphenyl)-p-toluidinomethyl]imidazoline, methanesulfonate
3-[(2-imidazolin-2-ylmethyl)(4-methylphenyl)amino]phenol, methanesulfonic acid
3-[[(4,5-Dihydro-1H-imidazol-2- yl)methyl](4-methylphenyl)-amino]phenol mesylate
3-[[(4,5-Dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)-amino]phenol mesylate
3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol; methanesulfonic acid
3-[N-(2-Imidazolin-2-ylmethyl)-p-toluidino]phenol methanesulphonate
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methyl-anilino]phenol; methanesulfonic acid
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol; methanesulfonic acid
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid
4CA-1013
50-60-2 (Parent)
65-28-1
A828197
A835046
AB0014005
AB2000443
AC-7472
AC1L3M27
AKOS007930193
AN-8957
AS-13800
BC200362
C17H19N3O.CH4O3S
C18H23N3O4S
CCG-222286
CCRIS 9022
CHEMBL1200873
CPD000059054
CS-2419
CTK8G2357
D00509
DR002120
DTXSID60215315
EINECS 200-604-6
EU-0100982
FT-0603267
HE375279
HMS2233A24
HMS3263E05
HMS3373D03
HMS3655B13
HY-B0362A
I14-0396
J10339
K062
KS-00000XQY
Lopac-P-7561
LP00982
LS-104726
m-(N-(2-Imidazolin-2-ylmethyl)-p-toluidino)phenol monomethanesulfonate (salt)
MCULE-3770473461
METHANESULFONIC ACID; PHENTOLAMINE
MFCD00134201
MLS000069487
MLS001076484
MolPort-003-959-154
NCGC00016195-01
NCGC00016195-02
NCGC00094282-01
NCGC00261667-01
NV-101
Opera_ID_1599
OraVerse
P 7561
P1985
Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt)
Phenol, m-(N-(2-imidazolin-2-ylmethyl)-p-toluidino)-, monomethanesulfonate (salt)
Phentolamine (mesylate)
phentolamine mesilate
Phentolamine mesilate (JAN/INN)
Phentolamine mesilate [INN:BAN]
Phentolamine mesilate for system suitability, European Pharmacopoeia (EP) Reference Standard
Phentolamine mesilate, European Pharmacopoeia (EP) Reference Standard
Phentolamine mesylate
Phentolamine mesylate (USP)
Phentolamine mesylate [USP]
Phentolamine Mesylate, pharmaceutical secondary standard; traceable to USP, PhEur
Phentolamine mesylate, United States Pharmacopeia (USP) Reference Standard
Phentolamine methanesulfonate
Phentolamine methanesulfonate salt
Phentolamine methanesulfonate salt, >=98% (TLC), powder
Phentolamine methanesulphonate
REGID_for_CID_91430
Regitin mesylate
Regitin methanesulphonate
Regitine (TN)
Regitine mesylate
Regitine methanesulfonate
s2038
SAM002703130
SCHEMBL40852
SMR000059054
SR-01000000055
SR-01000000055-3
ST057364
Tox21_500982
UNII-Y7543E5K9T
Vasofem
Vasomax
VZ33629
W-104799
Y7543E5K9T
Z-Max

US Patents and Regulatory Information for REGITINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis REGITINE phentolamine mesylate INJECTABLE;INJECTION 008278-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Citi
Baxter
Covington
Healthtrust
Federal Trade Commission
Fish and Richardson
Colorcon
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.